Initiation of Coverage Jade Biosciences Inc: High efficacy IgAN drug w/ pot‘l best in class dosing in $20B market - Initiate at BUY

研报英文原文证据摘录

Initiation of Coverage Jade Biosciences Inc: High efficacy IgAN drug w/ pot‘l best in class dosing in $20B market - Initiate at BUY

Forecast returns

Forecast price appreciation 193.4%

Forecast dividend yield 0.0%

Forecast stock return 193.4%

Market return assumption 9.1%

Forecast excess return 184.3%

Company Description

Jade Biosciences is a biotechnology company focused on discovering and developing

innovative therapies for serious diseases with unmet medical need. Its lead program is a

potential best-in-class drug for IgA nephropathy kidney disease. Leveraging advanced science

and a disciplined development strategy, the company aims to translate cutting-edge research

into differentiated clinical assets.

Valuation Method and Risk Statement

Our valuation is based on an EV/2035 sales multiple which we believe is an appropriate

methodology or early stage biotechnology companies. Key risks to our rating and price target

include: Clinical Risk: Early stage biotechs face high failure rates in clinical trials, where

unexpected safety signals or lack of efficacy can rapidly erode equity value; Regulatory Risk:

Regulatory pathways are uncertain, and delays, additional data requests, or outright FDA/

EMA rejections can materially impact timelines, cash needs, and valuations; Pricing Payer Risk:

Even after approval, reimbursement hurdles and increasingly aggressive payer scrutiny can

limit market access and undermine commercial projections; Competitive Risk: Intensifying

competition from larger, better capitalized peers or emerging modalities can compress peak

sales assumptions and shorten product lifecycles; Financing Dilution Risk: Limited revenue

and high burn rates force small cap biotechs to raise capital frequently, exposing investors to